[177Lu]Lu-DOTATATE Versus High-Dose Somatostatin Analogues in Advanced Gastroenteropancreatic Neuroendocrine Tumors: Pooled Evidence From 3 Phase 3 Randomized Trials
- 16 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
Abstract
Was not provided for this article.Keywords
This publication has 10 references indexed in Scilit:
- 177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trialAnnals of Oncology, 2025
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine TumorsNew England Journal of Medicine, 2025
- [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studyThe Lancet, 2024
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialThe Lancet Oncology, 2021
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsClinical Cancer Research, 2017
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2014
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011